Managing Adverse Events Associated With Immunotherapy in Bladder Cancer

January 12, 2019
Joaquim Bellmunt, MD, PhD

Joaquim Bellmunt, MD, PhD, shares his recommendation in how to manage the side effects of immunotherapy as a monotherapy, particularly PD-1/PD-L1, in patients with bladder cancer.

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, shares his recommendation for how to manage the side effects of immunotherapy as a monotherapy, particularly PD-1/PD-L1 agents, in patients with bladder cancer.

Bellmunt emphasizes that the side effects do not always appear right away in this patient population. If a side effect is not recognized early enough, it can become life threatening for a patient.